Skip to content
Peptide research

Ovagen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

Ovagen is a synthetic tripeptide marketed for liver, kidney, and gut protection plus anti-aging effects via gene regulation. Evidence is speculative, resting on mechanistic and animal studies rather than controlled human trials, so benefits remain unproven in people. There is no human safety data and long-term effects are unknown. It is not an approved US drug, and available product is unregulated, purity uncertain.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Ovagen is a tiny synthetic peptide made of just three amino acids (glutamic acid, aspartic acid, leucine) designed to support liver and gastrointestinal health. It was developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology as part of his decades-long research program into "peptide bioregulators" -- short peptides that he theorized could restore youthful gene expression patterns in specific organs. Ovagen targets liver cells and is proposed to work by crossing into the cell nucleus and directly influencing gene activity related to protein production and antioxidant defense.

How it works in the body

A bioregulator tripeptide (Glu-Asp-Leu) that targets liver and gastrointestinal cells. It interacts with gene regulatory regions in hepatocytes to normalize the expression of proteins involved in liver regeneration, detoxification, and the production of protective mucosal factors.

Research overview

Ovagen's evidence base is extremely narrow -- roughly 3-5 peer-reviewed studies directly examine this tripeptide, almost entirely from Khavinson's group. Lab studies show it increases cell growth and reduces aging markers (p53, p16, p21) in cell cultures, and demonstrates kidney-protective effects in rat models. The underlying theory -- that small peptides can cross into the nucleus and bind to specific DNA sequences to restore youthful gene expression -- is intriguing but not widely accepted outside Khavinson's circle. No clinical trials are registered on ClinicalTrials.gov for Ovagen. Professor Khavinson passed away in January 2024, and the future of this research program is uncertain. Consumers should approach this peptide with significant caution given the limited and non-independent evidence base.

Who researches Ovagen?

Commonly researched by

  • People researching GI and digestive health

    Studied for gastrointestinal protection, gut lining repair, or digestive support.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching kidney and renal health

    Studied for renal protective or nephroprotective effects.

  • People researching liver health

    Studied for hepatoprotective effects or liver function support.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • No human clinical safety data

    High

    Absence of evidence: no human trial of Glu-Asp-Leu indexed in PubMed; all located records are rat/in vitro

  • Unregulated product quality

    High

    FDA human drug compounding / bulk drug substances nominated for use in compounding: https://www.fda.gov/drugs/human-drug-compounding

  • Unknown long-term effects

    Moderate

    Absence of evidence: no chronic-toxicity or carcinogenicity study for Glu-Asp-Leu located in PubMed

  • Theoretical epigenetic risks

    Theoretical

    Mechanistic inference from PMID 27909961 (docking model) and PMID 25946838 (cell culture); no harm demonstrated in any study

  • Contraindicated in pregnancy/breastfeeding

    Moderate

    Absence of evidence: no reproductive or developmental toxicology for Glu-Asp-Leu located in PubMed or FDA sources

Interaction summary(8)

Rated by direction with this peptide

  • Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin)

    ProtectiveTheoretical

    In rats, EDL attenuated gentamicin-induced nephropathy — preventing oliguria and azotemia, reducing proteinuria, and preserving renal antioxidant enzyme activity (PMID 28744634). Gentamicin is the only aminoglycoside tested; tobramycin and amikacin are class extrapolation. Animal-only, single lab, no human data — never a substitute for creatinine and drug-level monitoring during aminoglycoside therapy.

    PMID 28744634 (rat, gentamicin only; other aminoglycosides extrapolated)

  • Cisplatin (and other platinum chemotherapy)

    CautionTheoretical

    Rat data are favorable — EDL restored diuresis, creatinine and glomerular filtration in cisplatin-induced acute renal failure and was the most effective peptide tested (PMID 26515176) — but for a person on platinum chemotherapy the operative unknown runs the other way: a peptide that increases proliferation and lowers p53 in culture has never been tested for whether it also shields tumor cells or blunts antitumor efficacy. Net direction during active treatment is caution, not protection; nephroprotection is rat-only and no oncology safety data exist either way.

    PMID 26515176 (rat nephroprotection); tumor-protection concern is inference from PMID 25946838, untested

  • Active malignancy / cytotoxic chemotherapy generally

    CautionTheoretical

    In rat renal cell culture EDL increased proliferation while lowering p16, p21 and p53 — the tumor-suppressor axis (PMID 25946838). Use alongside cancer treatment, or in anyone with undiagnosed neoplasia, is a mechanism-based concern extrapolated from one cell type; no tumor model or human data exist in either direction.

    PMID 25946838 (rat renal cell culture; no oncology model tested)

  • Nephrotoxic NSAIDs (ibuprofen, diclofenac, ketorolac) and iodinated contrast media

    NeutralTheoretical

    No study of EDL against NSAID or contrast nephropathy exists in any species. Any benefit is an unproven extrapolation from unrelated ischemia/reperfusion and toxic AKI models, so no protective claim can be made and it is no reason to relax hydration, dose limits, or renal monitoring.

    Absence of evidence: no NSAID or contrast-nephropathy study of Glu-Asp-Leu; extrapolation only from PMID 28744634

  • Calcineurin inhibitors (cyclosporine, tacrolimus)

    CautionTheoretical

    These drugs are both nephrotoxic and narrow-therapeutic-index. EDL altered diuresis and sodium handling in rats, so an unpredictable shift in trough levels is conceivable, but no interaction study exists in any species — dosing and level monitoring should never be changed on the basis of peptide use.

    Mechanistic inference from renal effects in PMID 28744634 / PMID 30607912; no interaction study published

  • Renally cleared narrow-index drugs (lithium, digoxin, methotrexate)

    CautionTheoretical

    EDL measurably changed urine output, sodium excretion and filtration rate in rats (PMID 28744634, 30607912), so a shift in renal clearance of these drugs is conceivable and levels would warrant watching — though no such interaction has been observed in any species and human relevance is unestablished.

    Mechanistic inference from PMID 28744634; PMID 30607912; no interaction study published

  • Known hepatotoxic drugs (acetaminophen, methotrexate, isoniazid, amiodarone)

    CautionTheoretical

    Despite Ovagen's marketing as a liver peptide, there is no hepatoprotection data for EDL in any species. The concern is behavioral rather than pharmacological: relying on an unproven agent while taking hepatotoxic medication risks substituting it for LFT monitoring and dose management. No pharmacokinetic interaction has been described or ruled out.

    Absence of evidence: no hepatic study of Glu-Asp-Leu located in PubMed/PMC

  • Injected insulin, GLP-1 agonists, and other prescription injectables

    NeutralTheoretical

    No pharmacokinetic or pharmacodynamic interaction between EDL and these agents has been described or tested. The practical concern is shared-technique sterility and product quality with an unregulated injectable, not any drug-level interaction.

    No interaction data published; FDA compounding safety concerns for unapproved peptides: https://www.fda.gov/drugs/human-drug-compounding

Known risks(5)

  • No human clinical safety data

    High

    No human clinical trials have been conducted for EDL/Ovagen specifically.

  • Unregulated product quality

    Moderate

    Purity and quality vary among unregulated products sold online and imported supplements.

  • Unknown long-term effects

    No longitudinal safety data in humans.

  • Theoretical epigenetic risks

    Theoretical

    Given proposed mechanism of direct DNA interaction and gene expression modulation, unpredictable effects cannot be ruled out.

  • Contraindicated in pregnancy/breastfeeding

    Moderate

    No safety data. Active liver emergencies also contraindicated.

Drug interactions(4)

  • Hepatotoxic drugs (acetaminophen, statins, methotrexate)

    Theoretical benefit but no clinical data. Do not rely on Ovagen to counteract drug-induced liver injury.

  • Immunosuppressants

    Theoretical concern — may modulate gene expression and immune pathways. No data available.

  • Other Khavinson bioregulators (Livagen, Vesugen)

    Livagen targets similar liver pathways. No formal interaction studies.

  • Chemotherapy agents

    Marketed as potentially protective against chemo-induced liver damage but no clinical evidence. Consult oncologist.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
5
Human Studies
0

All published research on EDL (Ovagen) is preclinical — in vitro cell culture and animal (rat) models. No registered clinical trials. The broader Khavinson program has extensive Russian clinical experience, but for other peptides (Thymalin, Cortexin), not Ovagen specifically.

Researched for(4)

Rated by confidence in the evidence

  • Anti-aging effects at the cellular level

    Low

    Single-lab rat kidney cell studies show reduced aging markers; no lifespan or human data.

    PMID 25946838; PMID 24958378; PMID 30607912

  • Nephroprotective effects

    Low

    Multiple animal studies show kidney protection in injury models; no human trials yet.

    PMID 28744634; PMID 26515176; PMID 30607912

  • GI mucosal protection

    Speculative

    No study of this peptide in gastrointestinal tissue; claim is purely theoretical.

    Absence of evidence: no PubMed/PMC record located for Glu-Asp-Leu and gastrointestinal mucosa

  • Epigenetic gene expression modulation

    Speculative

    Based on a computational docking model, not experimental DNA-binding data, unreplicated.

    PMID 27909961 (in silico docking); PMID 25946838; PMID 24958378

Benefits(5)

  • Hepatocellular protection and liver support

    Proposed from the Khavinson bioregulator framework. Direct Ovagen-specific clinical evidence is limited.

  • Anti-aging effects at the cellular level

    Khavinson et al. 2014 (Adv Gerontol): EDL decreased p16, p21, p53 expression while increasing Ki-67 and SIRT-6 in renal cell cultures.

  • Nephroprotective effects

    Zamorskii et al. 2017 (Bull Exp Biol Med): EDL prevented oliguria, reduced proteinuria, maintained antioxidant enzymes in rat models.

  • GI mucosal protection

    Proposed from broader Khavinson bioregulator program rather than EDL-specific studies.

  • Epigenetic gene expression modulation

    Khavinson et al. 2014: Molecular modeling predicted favorable EDL complexes with AT-rich DNA sequences in the minor groove. Direct sequence-specific transcriptional regulation was proposed.

Key studies(3)

  1. Zamorskii II, Shchudrova TS, Lin'kova NS, et al.

    Bulletin of Experimental Biology and Medicine

    2017

    EDL peptide produced nephroprotective effects: prevented oliguria, decreased proteinuria, maintained antioxidant enzymes, suppressed lipid peroxidation.

  2. Peptides regulate expression of signaling molecules in kidney cell cultures during in vitro aging

    In vitro cell culturePrimary kidney cell culturesIn vitro aging model

    Khavinson VKh, Lin'kova NS, Polyakova VO, et al.

    Bulletin of Experimental Biology and Medicine

    2014

    The study examined these markers across several peptide preparations. MMP-14 was identified as the target of EDL/T-35; cell-renewal effects were attributed to the renal polypeptide complex and AED/T-31.

  3. Tripeptides slow down aging process in renal cell culture

    In vitro cell cultureYoung and aged renal cell culturesIn vitro aging model

    Khavinson VKh, Tarnovskaia SI, Lin'kova NS, et al.

    Advances in Gerontology

    2014

    EDL increased cell proliferation, decreased p16/p21/p53, increased SIRT-6. Molecular modeling predicted favorable interaction with d(ATATATATAT)2 sequences in the DNA minor groove.

Regulation & availability

Why researchers look at it

A Khavinson bioregulator peptide (EDL tripeptide) that reduced aging markers (p53, p16, p21) in cell cultures and showed kidney-protective effects in rats. The evidence base is extremely narrow — roughly 3-5 studies, almost entirely from Khavinson's own group — with no registered clinical trials, no independent replication, and an uncertain research trajectory following Professor Khavinson's passing in January 2024.

Estimated cost
$30-80/mo oral capsules
FDA status
NOT FDA-approved. Never submitted for FDA review. No IND application. Not on FDA compounding lists. In Russia, registered as a biologically active food supplement. No Western regulatory agency has approved or reviewed Ovagen.
WADA status
Not specifically listed on WADA Prohibited List. However, WADA's S0 category prohibits non-approved substances, which could theoretically apply. Consult anti-doping authority before use.
Prescribability
Not prescribable as a pharmaceutical drug in any Western country. No FDA, EMA, or equivalent regulatory clearance. In Russia, registered as a biologically active food supplement. Does not require a prescription.
Availability
Available without prescription as Russian-manufactured capsules and sublingual drops (Ovagen Lingual), and through some US integrative medicine clinics. Not available from US compounding pharmacies.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(6)

  1. 1973
    Khavinson begins peptide bioregulator research at USSR Ministry of Defence laboratory.
  2. 1990s-2000s
    Six pharmaceutical peptides approved in Russia (Thymalin, Cortexin, etc.). Synthesized short peptides (Cytogens) including Ovagen developed.
  3. 2002
    Khavinson publishes 'Peptides and Ageing' monograph.
  4. 2014
    Key EDL research published on renal cell aging markers.
  5. 2017
    Zamorskii et al. publish EDL nephroprotection study.
  6. 2024-01-06
    Vladimir Khavinson dies at age 77 in Saint Petersburg.

Sources & FAQs

Research sources(6)

Frequently asked questions(4)

Is Ovagen the same as the KE dipeptide (Lys-Glu)?

No. Ovagen is the tripeptide EDL (Glu-Asp-Leu) targeting liver/GI. The KE dipeptide (Lys-Glu) is a separate peptide called Vilon targeting thymus/immune system.

Is there human clinical evidence for Ovagen?

No published human clinical trials exist specifically for EDL. All peer-reviewed evidence is preclinical.

How is Ovagen typically taken?

Oral capsules, sublingual drops, or subcutaneous injection.

Is Ovagen safe?

Generally well-tolerated based on limited data. No serious adverse effects reported. However, no large-scale human safety studies exist.